In 453 adults with moderate-to-severe plaque psoriasis responding to ustekinumab, repeated switching to biosimilar ABP 654 met pharmacokinetic similarity versus continued ustekinumab (AUCtau ratio 0.93, Cmax 0.95); efficacy, antidrug antibodies and adverse events were similar.
RCTn = 453
Blauvelt et al. Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded clinical trial to support interchangeability